Aldeyra Therapeutics (NASDAQ:ALDX) Receives “Outperform” Rating from Oppenheimer

Oppenheimer reiterated their outperform rating on shares of Aldeyra Therapeutics (NASDAQ:ALDX) in a research report sent to investors on Monday morning, Benzinga reports. Oppenheimer currently has a $10.00 target price on the biotechnology company’s stock.

ALDX has been the topic of a number of other research reports. HC Wainwright reissued a buy rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Tuesday, April 2nd. StockNews.com upgraded shares of Aldeyra Therapeutics from a sell rating to a hold rating in a report on Monday, January 29th.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ ALDX opened at $4.12 on Monday. The business’s fifty day moving average price is $3.71 and its 200-day moving average price is $3.22. Aldeyra Therapeutics has a one year low of $1.42 and a one year high of $11.97. The stock has a market capitalization of $244.77 million, a PE ratio of -8.08 and a beta of 1.45.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Thursday, March 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.13. As a group, equities analysts expect that Aldeyra Therapeutics will post -0.14 EPS for the current fiscal year.

Insider Activity

In other news, major shareholder Perceptive Advisors Llc acquired 37,712 shares of Aldeyra Therapeutics stock in a transaction on Friday, April 5th. The stock was acquired at an average cost of $4.74 per share, for a total transaction of $178,754.88. Following the purchase, the insider now owns 9,275,851 shares in the company, valued at $43,967,533.74. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Aldeyra Therapeutics news, major shareholder Perceptive Advisors Llc bought 37,712 shares of Aldeyra Therapeutics stock in a transaction on Friday, April 5th. The stock was acquired at an average price of $4.74 per share, with a total value of $178,754.88. Following the acquisition, the insider now owns 9,275,851 shares in the company, valued at $43,967,533.74. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Bruce Greenberg sold 13,201 shares of the business’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $3.41, for a total value of $45,015.41. Following the completion of the transaction, the insider now owns 120,699 shares of the company’s stock, valued at approximately $411,583.59. The disclosure for this sale can be found here. Over the last ninety days, insiders acquired 355,933 shares of company stock worth $1,473,245. Insiders own 7.30% of the company’s stock.

Institutional Trading of Aldeyra Therapeutics

A number of institutional investors have recently made changes to their positions in ALDX. Prime Capital Investment Advisors LLC bought a new position in Aldeyra Therapeutics during the fourth quarter valued at approximately $35,000. SG Americas Securities LLC purchased a new position in shares of Aldeyra Therapeutics in the 4th quarter worth $39,000. NorthRock Partners LLC bought a new stake in shares of Aldeyra Therapeutics in the fourth quarter worth $42,000. Kingswood Wealth Advisors LLC purchased a new stake in Aldeyra Therapeutics during the first quarter valued at $49,000. Finally, Tower Research Capital LLC TRC lifted its holdings in Aldeyra Therapeutics by 1,064.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 22,167 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 20,264 shares during the period. Hedge funds and other institutional investors own 59.71% of the company’s stock.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-?B, inflammasomes, and Scavenger Receptor A.